SPTX — Seaport Therapeutics Balance Sheet
0.000.00%
Annual balance sheet for Seaport Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Cash | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 309 | 216 |
| Net Total Receivables | 0 | 1.73 |
| Prepaid Expenses | ||
| Total Other Current Assets | ||
| Total Current Assets | 310 | 223 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 5.17 | 5.22 |
| Long Term Investments | ||
| Other Long Term Assets | ||
| Total Assets | 316 | 249 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 11.1 | 12.8 |
| Total Long Term Debt | ||
| Total Debt | ||
| Total Other Liabilities | ||
| Total Liabilities | 15.3 | 16.2 |
| Non Redeemable Preferred Stock | ||
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Other Equity | ||
| Total Equity | 300 | 233 |
| Total Liabilities & Shareholders' Equity | 316 | 249 |
| Total Common Shares Outstanding |